Analyzing ProMetic Life Sciences (OTCMKTS:PFSCF) and Mateon Therapeutics (OTCMKTS:MATN)

Insider & Institutional Ownership

0.1% of Mateon Therapeutics shares are held by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are held by institutional investors. 39.2% of Mateon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Mateon Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500.

Profitability

This table compares Mateon Therapeutics and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Valuation and Earnings

This table compares Mateon Therapeutics and ProMetic Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-2.33
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Mateon Therapeutics has higher earnings, but lower revenue than ProMetic Life Sciences.

Summary

Mateon Therapeutics beats ProMetic Life Sciences on 5 of the 8 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.